<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04494568</url>
  </required_header>
  <id_info>
    <org_study_id>HIFU-F-20.01</org_study_id>
    <nct_id>NCT04494568</nct_id>
  </id_info>
  <brief_title>Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Rectal Endometriosis</brief_title>
  <acronym>ENDO-HIFU-R1</acronym>
  <official_title>Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Rectal Endometriosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EDAP TMS S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EDAP TMS S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rectal endometriosis (RE) induces lesions associated with painful symptoms that can alter&#xD;
      quality of life. High Intensity Focused Ultrasound (HIFU) is a non-invasive ablative&#xD;
      procedure using a high-intensity ultrasound probe to induce tissue devitalization using&#xD;
      acoustic cavitation and thermal ablation. Focal One® is a transrectal HIFU device, which is&#xD;
      validated to treat prostatic cancer.&#xD;
&#xD;
      The primary objective of this clinical investigation is to evaluate the safety of the HIFU&#xD;
      treatment of rectal endometriosis with Focal One® HIFU device.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>INTERVENTIONAL, PROSPECTIVE, MULTICENTRIC, NON-RANDOMIZED AND NON-CONROLLED STUDY</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the tolerance of rectal endometriosis treatment with HIFU</measure>
    <time_frame>6 months</time_frame>
    <description>The tolerance of the treatment will be evaluated by the analysis of adverse events occurrence at 6 months post-HIFU treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the gynecological symptoms evolution of patients after HIFU treatment</measure>
    <time_frame>at 1 month, 3 months and 6 months post-intervention</time_frame>
    <description>EVA symptom Questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the of quality of life evolution of patients after HIFU treatment</measure>
    <time_frame>at 1 month, 3 months and 6 months post-intervention,</time_frame>
    <description>Quality of life questionnaire : MOS- SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the evolution of the nodule's volume</measure>
    <time_frame>at 6 months</time_frame>
    <description>The pre- and post-treatment comparison of the volume of the endometriodsis nodule measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the post-intervention analgesic treatment</measure>
    <time_frame>during the fisrt 10 days post treatment.</time_frame>
    <description>The level of medication during the fisrt 10 days post treatment will be studied by analysing the data collected in patient book.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the digestive symptoms evolution of patients after HIFU treatment</measure>
    <time_frame>at 1 month, 3 months and 6 months post-intervention</time_frame>
    <description>Wexner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the digestive symptoms evolution of patients after HIFU treatment</measure>
    <time_frame>at 1 month, 3 months and 6 months post-intervention</time_frame>
    <description>Kess questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the sexual symptoms evolution of patients after HIFU treatment</measure>
    <time_frame>at 1 month, 3 months and 6 months post-intervention</time_frame>
    <description>SFSI questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the urinary symptoms evolution of patients after HIFU treatment</measure>
    <time_frame>at 1 month, 3 months and 6 months post-intervention</time_frame>
    <description>USP questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Endometriosis, Rectum</condition>
  <arm_group>
    <arm_group_label>HIFU intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will benefit of an HIFU Treatment of their rectal endometriosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HIFU treatment</intervention_name>
    <description>HIFU Treatment of rectal endometriosis</description>
    <arm_group_label>HIFU intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged at least 25 years-old&#xD;
&#xD;
          -  Rectal endometriosis in preoperative imaging, without other digestive locations&#xD;
             (colon, ileum and small intentine)&#xD;
&#xD;
          -  Symptomatic patient refusing hormonal treatment and/or surgery.&#xD;
&#xD;
          -  Endometriosic nodule visible on echography with contrast and confirmed in Gadolinium&#xD;
             MRI and difusion sequence (according to standardized protocol)&#xD;
&#xD;
          -  Nodule with intrarectal protrusion of less than 50% (allowing the positioning of the&#xD;
             probe in front of the rectal nodule)&#xD;
&#xD;
          -  Distance from the upper pole to the anal margin ≤ 15 cm (measurement by MRI with&#xD;
             intra-rectal contrast)&#xD;
&#xD;
          -  No curent pregnancy (negative BHCG &lt;72h before the HIFU procedure) and no pregnancy&#xD;
             project within 6 months after the HIFU procedure (post-treatment MRI delay)&#xD;
&#xD;
          -  Patient agreeing not to change her hormone treatment for the duration of the study.&#xD;
&#xD;
          -  Patient accepting the study constraints&#xD;
&#xD;
          -  Health insurance affiliated patient or beneficiary of an equivalent coverage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Virgin patient&#xD;
&#xD;
          -  Ongoing uro-genital infection&#xD;
&#xD;
          -  Anorectal anatomy incompatible with HIFU therapy&#xD;
&#xD;
          -  History of segmental rectal resection with mechanical anastomosis, shaving or discoid&#xD;
             resection&#xD;
&#xD;
          -  Patient with an implant within 1cm of the treatment area (stent, catheter, ESSURE®&#xD;
             contraceptive implants).&#xD;
&#xD;
          -  Inflammatory colon disease (ulcerative colitis, Crohn's disease and others)&#xD;
&#xD;
          -  Latex allergy&#xD;
&#xD;
          -  Patient with contraindications to MRI&#xD;
&#xD;
          -  Patient with contraindications to Gadolinium injection&#xD;
&#xD;
          -  Patient previously treated with HIFU for a rectal endometriotic lesion&#xD;
&#xD;
          -  Patient not speaking nor reading French&#xD;
&#xD;
          -  Patient deprived of liberty following a legal or administrative decision&#xD;
&#xD;
          -  Patient under guardianship or tutelage measure&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gil DUBERNARD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire JOSSAN</last_name>
    <phone>04.72.15.31.50</phone>
    <email>Affaires-Cliniques@edap-tms.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe DESCAMPS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Tivoli-Ducos</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Horace Roman, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital BICETRE</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Herve FERNANDEZ, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de Gynécologie</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pierre COLLINET, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gil Dubernard, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rectal endometriosis, HIFU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

